商品名或批准名。第二部分。观点。医院药剂师。

Trade names or approved names. Part II. Points of view. The hospital pharmacist.

作者信息

Baker J A

出版信息

Postgrad Med J. 1974 Feb;50(580):83-4. doi: 10.1136/pgmj.50.580.83.

DOI:10.1136/pgmj.50.580.83

PMID:4465780

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2495474/

Abstract

In hospitals, the use of approved names for prescribing and labelling is an essential requirement for precision and safety in giving medicines. Substitution is an unavoidable consequence of using approved names which brings benefits, but creates problems that demand more widespread recognition and urgent attention. In particular, dangerous variations in response following brand changes can occur in patients stabilized on certain products. The Licensing Authority and the Pharmaceutical Industry have a responsibility to eliminate brand bio-availability differences. But there is an immediate need; firstly, to identify the small number of products where brand changes in patients stabilized on them can result in potentially dangerous variations in response; and secondly, to safeguard patients being treated with these products, by avoiding substitution and preventing inadvertent brand changes by including brand or manufacturer's names on labels and in all communications between hospital doctors and general practitioners. The complete elimination of substitution is not feasible and the indiscriminate use of brand names in hospitals causes confusion and increases risks of error in giving medicines.

摘要

在医院里，使用经批准的名称进行处方和标签标注是给药精准性和安全性的基本要求。药品替代是使用经批准名称不可避免的结果，它带来了益处，但也产生了一些问题，这些问题需要更广泛的认识和迫切的关注。特别是，在某些产品上病情已稳定的患者，更换品牌后可能会出现危险的反应差异。药品许可机构和制药行业有责任消除品牌生物利用度差异。但当下有迫切需求：首先，要确定少量的产品，对于使用这些产品病情已稳定的患者，更换品牌可能会导致潜在的危险反应差异；其次，要保护正在使用这些产品进行治疗的患者，通过避免替代，并在标签以及医院医生和全科医生之间的所有沟通中包含品牌或制造商名称，防止无意中更换品牌。完全消除替代是不可行的，而在医院里不加区分地使用品牌名称会造成混乱，并增加给药错误的风险。